Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab

• Published in: Clinical lung cancer Vol. 24; no. 6; pp. e205 - e213
• Main Authors: Delasos, Lukas, Wei, Wei, Hassan, Khaled A., Pennell, Nathan A., Patil, Pradnya, Stevenson, James
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023
• Subjects: Checkpoint inhibitor; Immunotherapy; Locally advanced non-small cell lung cancer; Recurrent non–small-cell lung cancer; Stage III non-small cell lung cancer; ALK; RET; CRT; NSCLC; OS; Locally advanced non-small cell lung cancer; BRAF; EGFR; R/R; Immunotherapy; ERBB2; PD-L1; KRAS; Stage III non-small cell lung cancer; PFS; MET; PD-1; ROS1; Checkpoint inhibitor; Recurrent non–small-cell lung cancer

Often, patients with NSCLC experience recurrent/refractory (R/R) disease within 2 years of chemoradiation (CRT) and consolidative durvalumab. Despite prior immune checkpoint inhibitor exposure, immunotherapy with or without chemotherapy is typically initiated if a driver-oncogene is absent. However,...